Propanc Biopharma Inc 's Cash & cash equivalent grew by 87.51 % in the Q4 2026 sequentially, while Current Liabilities decreased, this led to improvement in Propanc Biopharma Inc 's Quick Ratio to 0.25, above Propanc Biopharma Inc average Quick Ratio.

Within Major Pharmaceutical Preparations industry 415 other companies have achieved higher Quick Ratio than Propanc Biopharma Inc in fourth quarter 2026. While Quick Ratio total ranking has improved so far during the Q4 2026 to 3222, from total ranking in the third quarter 2026 at 3342.

Explain Quick Ratio?
How much Cash & cash equivalents PPCH�s has?
What are PPCH�s Current Liabilities?

Select the Comparisons :

None ▼

Select the Ratio:

Quick Ratio ▼

None ▼

Quick Ratio ▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/PPCH/financial-strength

https://api.csimarket.com/api/v1/companies/PPCH/fundamentals

https://api.csimarket.com/api/v1/companies/PPCH/fundamentals?mode=as_of&as_of=YYYY-MM-DD

Programmatic access for models, analytics, and integration workflows.

Explore the Financial Data API

Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery

Connect Your AI Assistant

How to Connect Your AI Assistant to CSIMarket MCP MCP Server

Access this full dataset via API

Free sample Full docs All endpoints

PPCH Quick Ratio	(Jun 30 2026) Q4	(Mar 31 2026) Q3	(Dec 31 2025) Q2	(Sep 30 2025) Q1	(Jun 30 2025) Q4
Y / Y Current Liabilities Change	-39.87 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent Change	6782.91 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio MRQ	0.25	Subscribe	Subscribe	Subscribe	Subscribe
PPCH's Total Ranking	# 3222	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities Change	-3.49 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent Change	87.51 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick Ratio fourth quarter 2026 Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 416
Healthcare Sector	# 807
Overall Market	# 3222

Quick Ratio Statistics
High	Average	Low
0.29	0.03	0
(Mar 31 2016)		(Mar 31 2014)

Financial Statements
Propanc Biopharma Inc 's Current Liabilities	$ 3 Millions	Visit PPCH's Balance sheet
Propanc Biopharma Inc 's Cash & cash equivalent	$ 1 Millions	Visit PPCH's Balance sheet
Source of PPCH's Sales		Visit PPCH's Sales by Geography

Cumulative Propanc Biopharma Inc 's Quick Ratio

PPCH's Quick Ratio for the trailling 12 Months

PPCH Quick Ratio	(Jun 30 2026) 12 Months	(Mar 31 2026) 12 Months	(Dec 31 2025) 12 Months	(Sep 30 2025) 12 Months	(Jun 30 2025) 12 Months
Y / Y Current Liabilities TTM Growth	-22.83 %	Subscribe	Subscribe	Subscribe	Subscribe
Y / Y Cash & cash equivalent TTM Growth	2712.35 %	Subscribe	Subscribe	Subscribe	Subscribe
Quick Ratio TTM	0.17	Subscribe	Subscribe	Subscribe	Subscribe
Total Ranking TTM	# 4109	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Current Liabilities TTM Growth	-13.68 %	Subscribe	Subscribe	Subscribe	Subscribe
Seq. Cash & cash equivalent TTM Growth	50.62 %	Subscribe	Subscribe	Subscribe	Subscribe

Quick ratio ranking by company, industry and sector >> Back to PPCH Financial Strength Comparisons >> Go to Compare PPCH Quick Ratio to its Competitors

On the trailing twelve months basis PPCH Cash & cash equivalent more than doubled by 6782.91 % in Q4 2026 year on year, while Current Liabilities decreased to $3 millions, this led to increase in in Propanc Biopharma Inc 's Quick Ratio to 0.17, above PPCH average Quick Ratio.
Quick Ratio is the average cumulative value over the last four quarters.

Among companies operating within Major Pharmaceutical Preparations industry 443 other companies have achieved higher Quick Ratio than Propanc Biopharma Inc . While Quick Ratio overall ranking has improved so far to 4109, from total ranking during the twelve months ending third quarter 2026 at 4120.

Explain Quick Ratio?
How much Cash & cash equivalents PPCH�s has?
What are PPCH�s Current Liabilities?

TTM Quick Ratio Company Ranking
Within:	No.
Within the Major Pharmaceutical Preparations Industry	# 444
Healthcare Sector	# 911
Within the Market	# 4109

trailing twelve months Quick Ratio Statistics
High	Average	Low
0.19	0.03	0
(Sep 30 2016)		(Jun 30 2013)

Companies with similar Quick Ratio in the quarter ending Jun 30 2026, within Major Pharmaceutical Preparations Industry	Quick Ratio	Jun 30 2026 MRQ Cash & cash equivalent	Jun 30 2026 MRQ Current Liabilities
Zentalis Pharmaceuticals Inc	0.66	$ 24.783 Millions	$ 37.709 Millions
Pfizer Inc	0.64	$ 20,881.000 Millions	$ 32,646.000 Millions
Enanta Pharmaceuticals Inc	0.62	$ 33.419 Millions	$ 54.166 Millions
60 Degrees Pharmaceuticals Inc	0.61	$ 1.023 Millions	$ 1.685 Millions
Eton Pharmaceuticals Inc	0.59	$ 26.845 Millions	$ 45.124 Millions
Kura Oncology Inc	0.59	$ 70.242 Millions	$ 118.193 Millions
Allarity Therapeutics Inc	0.59	$ 16.982 Millions	$ 28.579 Millions
Bristol myers Squibb Company	0.59	$ 11,067.000 Millions	$ 18,659.000 Millions
Prestige Consumer Healthcare Inc	0.58	$ 89.127 Millions	$ 153.806 Millions
Biora Therapeutics Inc	0.57	$ 21.906 Millions	$ 38.687 Millions
Matinas Biopharma Holdings Inc	0.56	$ 0.761 Millions	$ 1.350 Millions
Karyopharm Therapeutics Inc	0.56	$ 75.225 Millions	$ 134.233 Millions
Journey Medical Corp	0.56	$ 25.643 Millions	$ 45.770 Millions
Nektar Therapeutics	0.55	$ 39.267 Millions	$ 70.985 Millions
Supernus Pharmaceuticals inc	0.52	$ 180.145 Millions	$ 347.378 Millions
Citius Oncology Inc	0.50	$ 16.564 Millions	$ 33.152 Millions
Verrica Pharmaceuticals Inc	0.50	$ 11.198 Millions	$ 22.442 Millions
Aytu Biopharma Inc	0.48	$ 26.308 Millions	$ 54.659 Millions
Jupiter Neurosciences Inc	0.47	$ 1.522 Millions	$ 3.251 Millions
Aeon Biopharma inc	0.47	$ 3.431 Millions	$ 7.342 Millions
Evolus Inc	0.46	$ 45.170 Millions	$ 98.731 Millions
Biomarin Pharmaceutical Inc	0.45	$ 874.005 Millions	$ 1,927.164 Millions
Pds Biotechnology Corp	0.45	$ 5.596 Millions	$ 12.377 Millions
Biofrontera Inc	0.44	$ 4.659 Millions	$ 10.541 Millions
Beyondspring Inc	0.43	$ 10.361 Millions	$ 23.834 Millions
Organon and Co	0.43	$ 1,132.000 Millions	$ 2,616.000 Millions
Gossamer Bio Inc	0.41	$ 57.026 Millions	$ 137.783 Millions
Bausch Health Companies Inc	0.39	$ 1,825.000 Millions	$ 4,687.000 Millions
Johnson and Johnson	0.38	$ 21,094.000 Millions	$ 54,895.000 Millions
Telix Pharmaceuticals Ltd	0.37	$ 251.910 Millions	$ 674.369 Millions

Date modified: 2026-10-05T11:03:41+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.